Claire Coeshott

Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3

Claire Coeshott, Christie Ohnemus, Anna Pilyavskaya et al. · Proceedings of the National Academy of Sciences · 1999 · 357 citations

Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity

A.C. Stubbs, Kathleen S. Martin, Claire Coeshott et al. · Nature Medicine · 2001 · 212 citations

Vaccination, Cross-protection, Vaccine Development +8

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Anuj Gaggar, Claire Coeshott, David Apelian et al. · Vaccine · 2014 · 100 citations · Full text

ProJuvant™ (Pluronic F127®/chitosan) enhances the immune response to intranasally administered tetanus toxoid

M.A. Julie Westerink, S. Louise Smithson, N C Srivastava et al. · Vaccine · 2001 · 83 citations

Inflammation, Tetanus Toxoid, Medicine +8

Pluronic® F127-based systemic vaccine delivery systems

Claire Coeshott, S. Louise Smithson, Evie L. Verderber et al. · Vaccine · 2004 · 82 citations

Vaccination, Mucosal Vaccination, Cross-protection +7